VXRT Vaxart Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VXRT

Price (delayed)

$0.7289

Market cap

$126.73M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.57

Enterprise value

$112.06M

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can ...

Highlights
VXRT's revenue has surged by 78% since the previous quarter
VXRT's gross profit has surged by 78% since the previous quarter
VXRT's debt is up by 12% QoQ but it is down by 7% YoY
The equity has contracted by 48% YoY and by 19% from the previous quarter
VXRT's quick ratio is down by 42% year-on-year and by 34% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://vaxart.com
Peers: NWBO

Key stats

What are the main financial stats of VXRT
Market
Shares outstanding
173.86M
Market cap
$126.73M
Enterprise value
$112.06M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.92
Price to sales (P/S)
14.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.19
Earnings
Revenue
$7.38M
EBIT
-$82.2M
EBITDA
-$73.58M
Free cash flow
-$72.2M
Per share
EPS
-$0.57
Free cash flow per share
-$0.5
Book value per share
$0.38
Revenue per share
$0.05
TBVPS
$0.57
Balance sheet
Total assets
$91.83M
Total liabilities
$34.03M
Debt
$20.09M
Equity
$57.81M
Working capital
$31.81M
Liquidity
Debt to equity
0.35
Current ratio
3.32
Quick ratio
3.11
Net debt/EBITDA
0.2
Margins
EBITDA margin
-997.2%
Gross margin
100%
Net margin
-1,117.6%
Operating margin
-1,129.5%
Efficiency
Return on assets
-73.3%
Return on equity
-108.5%
Return on invested capital
-117.4%
Return on capital employed
-105.2%
Return on sales
-1,114%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VXRT stock price

How has the Vaxart stock price performed over time
Intraday
-2.81%
1 week
2.66%
1 month
-40.74%
1 year
-16.6%
YTD
27.25%
QTD
-43.93%

Financial performance

How have Vaxart's revenue and profit performed over time
Revenue
$7.38M
Gross profit
$7.38M
Operating income
-$83.35M
Net income
-$82.47M
Gross margin
100%
Net margin
-1,117.6%
The operating margin has surged by 99% year-on-year and by 52% since the previous quarter
VXRT's net margin has soared by 99% YoY and by 48% QoQ
VXRT's revenue has surged by 78% since the previous quarter
VXRT's gross profit has surged by 78% since the previous quarter

Growth

What is Vaxart's growth rate over time

Valuation

What is Vaxart stock price valuation
P/E
N/A
P/B
1.92
P/S
14.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.19
The EPS has increased by 32% year-on-year and by 11% since the previous quarter
The equity has contracted by 48% YoY and by 19% from the previous quarter
The P/B is 45% below the 5-year quarterly average of 3.5 but 37% above the last 4 quarters average of 1.4
VXRT's P/S is 97% below its 5-year quarterly average of 466.8 and 76% below its last 4 quarters average of 58.8
VXRT's revenue has surged by 78% since the previous quarter

Efficiency

How efficient is Vaxart business performance
The return on sales has surged by 99% year-on-year and by 48% since the previous quarter
Vaxart's ROE has decreased by 36% YoY and by 9% from the previous quarter
The ROA has contracted by 21% YoY and by 5% from the previous quarter
The company's return on invested capital fell by 8% QoQ but it rose by 4.8% YoY

Dividends

What is VXRT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VXRT.

Financial health

How did Vaxart financials performed over time
The company's total assets is 170% higher than its total liabilities
VXRT's quick ratio is down by 42% year-on-year and by 34% since the previous quarter
Vaxart's current ratio has decreased by 40% YoY and by 35% QoQ
VXRT's debt is 65% lower than its equity
Vaxart's debt to equity has surged by 75% YoY and by 40% QoQ
The equity has contracted by 48% YoY and by 19% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.